{
    "nctId": "NCT05891561",
    "briefTitle": "Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer",
    "officialTitle": "Short-course Trastuzumab, Pertuzumab Combined With Taxanes in the Adjuvant Treatment of Early Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: an Open-label, Single-arm Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Disease free survival [DFS]",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically diagnosed unilateral primary invasive breast cancer patient with pT1, pN0, and M0 disease\n* HER2-positive, ie. immunohistochemistry \\[IHC\\] 3+ or IHC 2+ and fluorescence in situ hybridisation \\[FISH\\]-positive according to ASCO/CAP 2018 guidelines\n* complete clinical pathological information\n* Eastern Cooperative oncology Group \\[ECOG\\] 0-1\n* Currently not pregnant or breast-feeding\n* Fine organ function\n* Have good compliance with planned treatment, understand the study process and sign a written informed consent\n\nExclusion Criteria:\n\n* Bilateral or metastatic breast cancer\n* Receiving neoadjuvant treatment\n* Other malignancies within 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer\n* Severe systemic infections or other serious illnesses\n* HIV infection, active hepatitis B or C infection\n* Known allergy to or intolerance to a therapeutic drug or its excipients\n* Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason\n* Enrollment of another investigational study within 4 weeks prior to initial administration of the investigational treatment\n* Receiving live vaccine within 30 days prior to initial administration of the investigational treatment\n* History of mental illness or drug abuse that may affect compliance with the trial requirements\n* The researchers determine that the patients were not suitable for the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}